# Medpace Holdings, Inc. – Consensus ‘buy’ rating and 11.1% Upside Potential

- Link: https://www.directorstalkinterviews.com/medpace-holdings-inc.consensus-buy-rating-and-11.1-upside-potential/4121131733
- Published: 2023-11-01T14:29:08+00:00
- Author: Charlotte Edwards

**Medpace Holdings, Inc.** with ticker code (MEDP) now have 4 market analysts covering
the stock. The analyst consensus now points to a rating of ‘buy’. The target price
High/Low ranges between $273.00 and $265.00 suggesting an average Analsyt target
price of $269.50. Now with the previous closing price of $242.67 this is indicating
there is a potential upside of 11.1%. The 50 day moving average now sits at $253.39
and the 200 moving average now moves to $226.06. The company has a market cap of
7.37B. The stock price for the company is currently $240.34 USD

 The potential market cap would be $8,189,779,414 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 28.21, revenue per share of $57.77
and a 14.47% return on assets.

Medpace Holdings, Inc. is a global provider of clinical research-based drug and 
medical device development services. The Company is focused on providing scientifically
driven outsourced clinical development services to the biotechnology, pharmaceutical
and medical device industries. The Company partners with pharmaceutical, biotechnology,
and medical device companies in the development and execution of clinical trials.
The Company’s drug development services focuses on full-service Phase I-IV clinical
development services and include development plan design, coordinated central laboratory,
project management, regulatory affairs, clinical monitoring, data management and
analysis, pharmacovigilance new drug application submissions, and post-marketing
clinical support. It also provides bio-analytical laboratory services, clinical 
human pharmacology, imaging services, and electrocardiography reading support for
clinical trials. Its operations are based in North America, Europe, and Asia.

Share on: